Webinar: How to Reduce Big Pharma’s Influence on Guidelines
This webinar, containing the presentation slides, is now available. Downloading, copying, reusing, or distributing this document is not permissible.
This informative webinar focused on the ways in which the pharmaceutical industry influences clinical practice guideline development through involvement in clinical studies, providing funding to clinical experts who sit on guideline panels, developing their own clinical guidelines through affiliated companies and more, and what guideline developers can do to minimize this influence on guideline development.
Recording of the webinar
- Nov 13, 2014
- not set
- 1:30 hours
Peter Gøtzsche, MD
Nordic Cochrane Centre
Peter C. Gøtzsche, MD is a specialist in internal medicine, cofounder of The Cochrane Collaboration, director of The Nordic Cochrane Centre, and was an editor in the Cochrane Methodology Review Group for 17 years. He worked with clinical trials and regulatory affairs in the drug industry (1975-83), and at hospitals in Copenhagen (1984-95). He became professor of Clinical Research Design and Analysis in 2010 at the University of Copenhagen, and has had a long-term interest in statistics and research methodology. Dr. Gøtzsche has published more than 70 papers in “the big five” medical journals (BMJ, Lancet, JAMA, Annals of Internal Medicine and New England Journal of Medicine) and his scientific works have been cited over 15,000 times. He is a member of several groups publishing guidelines for good reporting of research and has coauthored CONSORT for randomized trials (www.consort-statement.org), STROBE for observational studies (), PRISMA for systematic reviews and meta- analyses (www.prisma-statement.org), and SPIRIT for trial protocols ( www.spirit-statement.org ). Peter Gøtzsche is the author of the thought-provoking books, Deadly Medicines and Organised Crime: How Big Pharma Has Corrupted Healthcare, Mammography Screening: Truth, Lies and Controversy, and Rational Diagnosis and Treatment: Evidence-Based Clinical Decision-Making.
Chair, G-I-N North America Steering Group
1. Learn how the pharmaceutical industry influences clinical trials and guideline development.
2. Understand the implications of pharmaceutical industry involvement.
3. Learn what you can do to minimize the influence of Big Pharma on guideline development.